4 completed, 3 recruiting, 2 active not recruiting, 1 terminated. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 4, Recruiting 3, Active not recruiting 2, Terminated 1 |
Follow Atypical Hemolytic Uremic Syndrome: new trials by email Literature Review of Atypical Hemolytic Uremic Syndrome trials Research Report on Atypical Hemolytic Uremic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-02-28 | 2026-04-29 |
| Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome Soliris®, Renin angiotensin system blockers - Hypertensive Emergency-associated Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2023-11-09 | 2024-01-05 |
| Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Iptacopan - Atypical Hemolytic Uremic Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 34 | 2022-01-17 | 2026-08-07 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 41 | 2021-11-17 | 2026-10-01 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | Hoffmann-La Roche | 83 | 2021-10-22 | 2026-10-30 |
| Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) Spacing of Eculizumab infusions - Hemolytic-Uremic Syndrome, Atypical | Phase 3 | Completed | University Hospital, Tours | 40 | 2021-10-20 | 2025-03-25 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome OMS721 (narsoplimab) - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 3 | Terminated | Omeros Corporation | 6 | 2018-05-02 | 2025-12-10 |
| Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Ravulizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 34 | 2017-08-31 | 2024-03-15 |
| Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Ravulizumab - Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2017-01-11 | 2024-02-20 |
Thrombotic Microangiopathies (5) · Acute Kidney Injury (1) · Glomerulonephritis, Membranoproliferative (1) · Hemolytic-Uremic Syndrome (1) · Hypertensive Crisis (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1)
Anemia (10) · Anemia, Hemolytic (10) · Blood Platelet Disorders (10) · Cytopenia (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Male Urogenital Diseases (10) · Thrombocytopenia (10) · Uremia (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Hemolytic-Uremic Syndrome (9) · Kidney Diseases (9)
iptacopan (2) · ravulizumab (2) · eculizumab (1) · narsoplimab (1)
Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (2) · Hoffmann-La Roche (2) · Assistance Publique - Hôpitaux de Paris (1) · Omeros Corporation (1) · University Hospital, Tours (1)
France (6) · Japan (6) · United States (6) · China (5) · Belgium (4) · Brazil (4) · Germany (4) · India (4) · Italy (4) · Spain (4) · Canada (3) · Poland (3) · South Korea (3) · Taiwan (3) · Turkey (Türkiye) (3)
PMID 33783815, PMID 32299680, PMID 33048203, PMID 33407224, PMID 34169200, PMID 36329366, PMID 39105067, PMID 39468592
2016 (2), 2023 (2)